Skip to content

CRISPR Therapeutics

US · CRSP #2057 by market cap Listed 2016
39.10 +0.17 +0.44%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:54

Recent news

  • Rating change
    Citi Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Maintains Target Price $90
    Market Newswire · 2026/11/9
  • UBS Maintains CRISPR Therapeutics(CRSP.US) With Hold Rating, Maintains Target Price $52
    Market Newswire · 2026/11/10
  • Rating change
    A Quick Look at Today's Ratings for CRISPR Therapeutics(CRSP.US), With a Forecast Between $50 to $110
    Market Newswire · 2026/11/4
  • Company notice
    CRISPR Therapeutics | SCHEDULE 13G/A: Others
    SEC · 2026/11/14
  • Rating change
    Citi Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Raises Target Price to $90
    Market Newswire · 2026/11/4
  • Rating change
    Wells Fargo Maintains Equal-Weight on CRISPR Therapeutics, Lowers Price Target to $70
    Benzinga · 2026/11/4
  • Rating change
    Crispr Therapeutics Price Target Raised to $90.00/Share From $88.00 by Citigroup
    Dow Jones · 2026/11/5
  • Rating change
    Crispr Therapeutics Price Target Maintained With a $82.00/Share by Needham
    Dow Jones · 2026/11/3
  • Company notice
    CRISPR Therapeutics | SCHEDULE 13G: Others
    SEC · 2026/11/10
  • Needham Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Maintains Target Price $82
    Market Newswire · 2026/11/10
  • CRISPR Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
    GlobeNewswire · 2026/11/10
  • Company notice
    CRISPR Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
    SEC · 2026/11/7
  • Rating change
    Citigroup Maintains Buy on CRISPR Therapeutics, Raises Price Target to $90
    Benzinga · 2026/11/5
  • Rating change
    Needham Reiterates Buy on CRISPR Therapeutics, Maintains $82 Price Target
    Benzinga · 2026/11/3
  • Rating change
    Crispr Therapeutics Is Maintained at Buy by Citigroup
    Dow Jones · 2026/11/5
  • Rating change
    BofA Securities Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Cuts Target Price to $80
    Market Newswire · 2026/11/4
  • Company notice
    CRISPR Therapeutics | 3: Initial statement of beneficial ownership of securities- Sakhamuri Sivakesava
    SEC · 2026/11/3
  • CRISPR Therapeutics Presents Phase 1b Data for CTX310® Demonstrating Reductions in ANGPTL3 and Triglycerides in Patients With Severe Hypertriglyceridemia at the American Heart Association (AHA) Scientific Sessions 2026
    GlobeNewswire · 2026/11/9
  • Company notice
    CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Sakhamuri Sivakesava
    SEC · 2026/11/7
  • A Quick Look at Today's Ratings for CRISPR Therapeutics(CRSP.US), With a Forecast Between $67 to $110
    Market Newswire · 2026/11/10
  • Rating change
    Crispr Therapeutics AG (CRSP) Receives a New Rating From a Top Analyst
    TipRanks · 2026/10/15
  • Rating change
    Crispr Therapeutics Initiated at Neutral by UBS
    Dow Jones · 2026/10/16
  • Company notice
    CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Silver Andrew Jacob
    SEC · 2026/10/29
  • Rating change
    Crispr Therapeutics Price Target Announced at $52.00/Share by UBS
    Dow Jones · 2026/10/16
  • Rating change
    H.C. Wainwright Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Maintains Target Price $80
    Market Newswire · 2026/10/9

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 19:54:43 · For reference only, not investment advice and not tailored to your situation.

CRISPR Therapeutics discussion 0 comments

Add a comment